ScoreComparison
Company
Score
Quality
Valuation
Financial
Technical
Why is Catalyst Pharmaceuticals, Inc. ?
1
Strong Long Term Fundamental Strength with an average Return on Equity (ROE) of 25.28%
- Healthy long term growth as Net Sales has grown by an annual rate of 37.37% and Operating profit at 44.77%
- Company has a low Debt to Equity ratio (avg) at times
2
With a growth in Net Sales of 7.61%, the company declared Very Positive results in Sep 25
- The company has declared positive results for the last 4 consecutive quarters
- OPERATING CASH FLOW(Y) Highest at USD 234.66 MM
- DEBT-EQUITY RATIO (HY) Lowest at -74.65 %
- PRE-TAX PROFIT(Q) Highest at USD 73.12 MM
3
With ROE of 23.27%, it has a attractive valuation with a 3.09 Price to Book Value
- The stock is trading at a premium compared to its peers' average historical valuations
- Over the past year, while the stock has generated a return of 3.22%, its profits have risen by 48.7% ; the PEG ratio of the company is 0.3
4
Rising Promoter Confidence
- Promoters have increased their stake in the company by 1.62% over the previous quarter and currently hold 4.35% of the company
- Promoters increasing their stake is a sign of high confidence in the future of the business
Real-Time Research ReportHow much should you buy?
- Overall Portfolio exposure to Catalyst Pharmaceuticals, Inc. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Catalyst Pharmaceuticals, Inc. for you?
Medium Risk, High Return
Absolute
Risk Adjusted
Volatility
Catalyst Pharmaceuticals, Inc.
3.22%
1.30
35.11%
S&P 500
14.9%
0.77
19.29%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
37.37%
EBIT Growth (5y)
44.77%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.73
Sales to Capital Employed (avg)
0.76
Tax Ratio
23.64%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
92.91%
ROCE (avg)
116.28%
ROE (avg)
25.28%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
13
Industry P/E
Price to Book Value
3.09
EV to EBIT
8.33
EV to EBITDA
7.27
EV to Capital Employed
9.34
EV to Sales
3.73
PEG Ratio
0.29
Dividend Yield
NA
ROCE (Latest)
112.13%
ROE (Latest)
23.27%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Sideways
Sideways
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Mildly Bearish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
No Trend
Mildly Bullish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend14What is working for the Company
OPERATING CASH FLOW(Y)
Highest at USD 234.66 MM
DEBT-EQUITY RATIO
(HY)
Lowest at -74.65 %
PRE-TAX PROFIT(Q)
Highest at USD 73.12 MM
RAW MATERIAL COST(Y)
Fallen by -0.89% (YoY
NET PROFIT(9M)
Higher at USD 163.3 MM
CASH AND EQV(HY)
Highest at USD 1,342.69 MM
NET SALES(Q)
Highest at USD 148.39 MM
-3What is not working for the Company
DEBTORS TURNOVER RATIO(HY)
Lowest at 7.01 times
INVENTORY TURNOVER RATIO(HY)
Lowest at 5 times
Here's what is working for Catalyst Pharmaceuticals, Inc.
Operating Cash Flow
Highest at USD 234.66 MM and Grown
In each year in the last three yearsMOJO Watch
The company has generated higher cash revenues from business operations
Operating Cash Flows (USD MM)
Pre-Tax Profit
Highest at USD 73.12 MM and Grown
In each period in the last five periodsMOJO Watch
Near term Pre-Tax Profit trend is very positive
Pre-Tax Profit (USD MM)
Debt-Equity Ratio
Lowest at -74.65 % and Grown
In each half year in the last five Semi-Annual periodsMOJO Watch
The company has been reducing its borrowing as compared to equity capital
Debt-Equity Ratio
Net Profit
At USD 163.3 MM has Grown at 49.58%
Year on Year (YoY)MOJO Watch
Near term Net Profit trend is positive
Net Profit (USD MM)
Net Sales
Highest at USD 148.39 MM
in the last five periodsMOJO Watch
Near term sales trend is positive
Net Sales (USD MM)
Cash and Eqv
Highest at USD 1,342.69 MM
in the last six Semi-Annual periodsMOJO Watch
Short Term liquidity is improving
Cash and Cash Equivalents
Net Profit
Higher at USD 163.3 MM
than preceding 12 month period ended Sep 2025MOJO Watch
In the nine month period the company has already crossed sales of the previous twelve months
Net Profit (USD MM)
Raw Material Cost
Fallen by -0.89% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for Catalyst Pharmaceuticals, Inc.
Debtors Turnover Ratio
Lowest at 7.01 times and Fallen
In each half year in the last five Semi-Annual periodsMOJO Watch
Company's pace of selling Debtors has slowed
Debtors Turnover Ratio
Inventory Turnover Ratio
Lowest at 5 times
in the last five Semi-Annual periodsMOJO Watch
Company's pace of selling inventory has slowed
Inventory Turnover Ratio
Non Operating Income
Highest at USD 0.1 MM
in the last five periodsMOJO Watch
Increased income from non business activities may not be sustainable
Non Operating income
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
